Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

1.220 -0.180 (-12.84%)
Streaming Delayed Price Updated: 11:53 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Skye Bioscience, Inc. - Common Stock

Earnings Scheduled For March 20, 2025
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Tuesday's session: top gainers and losers
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Top Picks For 2025: Skye Bioscience
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects.... 
Via Talk Markets
Topics Stocks / Equities
MarketBeat Week in Review – 10/7 - 10/11
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. 
Via MarketBeat
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus... 
Via Benzinga
US Stocks Edge Lower; FedEx Earnings Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
From Beacon Biosignals
Via GlobeNewswire
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
The company is focusing on obesity treatment after its glaucoma drug failed. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.